ADAM8 and cancer: Broad-spectrum metalloprotease inhibitorssuch as marimastat have failed in clinical trials for cancer due tomuscoloskeletal side effects and toxicity.10 On the contrary, a selective inhibition of ADAM8 has been achievedby Schlomann et al.7 using an exosite inhibitor,a short cyclic peptide designed to block ADAM8 activation by interactingwith the DIS domain.